Loading
A phase 1/2 trial of EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant and Exemestane in HR-positive / HER2-negative breast cancer, run by Ellipses Pharma, now recruiting.
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer is a phase 1/2 interventional study registered as NCT05573126 by Ellipses Pharma, with 95 participants planned, started 2023-01-11 and due to reach its primary completion in 2028-02. Interventions recorded: EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant and Exemestane.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Exemestane, Everolimus, Fulvestrant and the tag pipeline.
Shares Exemestane, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Exemestane, Abemaciclib, Fulvestrant and the tag pipeline.
Shares Exemestane, Fulvestrant and the tag pipeline.
Shares Abemaciclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Abemaciclib, Fulvestrant and the tag pipeline.
Shares Elacestrant, Exemestane and the tag pipeline.
Shares Abemaciclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/